High rates of primary Mycobacterium avium complex and Pneumocystis jiroveci prophylaxis in the United States
- PMID: 16116306
- DOI: 10.1097/01.mlr.0000175631.34438.1e
High rates of primary Mycobacterium avium complex and Pneumocystis jiroveci prophylaxis in the United States
Abstract
Background: National data from the mid-1990s demonstrated that many eligible patients with HIV infection do not receive prophylaxis for opportunistic infections (OIs) and that racial and gender disparities existed in OI prophylaxis receipt.
Objective: We examined whether demographic disparities in use of OI prophylaxis persist in 2001 and if outpatient care is associated with OI prophylaxis utilization.
Research design: Demographic, clinical, and pharmacy utilization data were collected from 10 U.S. HIV primary care sites in the HIV Research Network.
Subjects: This study consisted of adult patients (>or=18 years old) in longitudinal HIV primary care.
Measures: Indications for Pneumocystis jiroveci pneumonia (PCP) or Mycobacterium avium complex (MAC) prophylaxis were 2 or more CD4 counts less than 200 or 50 cells/mm(3) during calendar year (CY) 2001, respectively. Using multivariate logistic regression, we examined demographic and clinical characteristics associated with receipt of PCP or MAC prophylaxis and the association of outpatient utilization with appropriate OI prophylaxis.
Results: Among eligible patients, 88.1% received PCP prophylaxis and 87.6% received MAC prophylaxis. Approximately 80% had 4 or more outpatient visits during CY 2001. Adjusting for care site, male gender (odds ratio [OR], 1.47), Medicare coverage (OR, 1.60), and having 4 or more outpatient visits in a year (OR, 2.34) were significantly associated with increased likelihood of PCP prophylaxis. Adjusting for care site, having 4 or more outpatient visits in a year (OR, 1.85) was associated with increased likelihood of receipt of MAC prophylaxis. There were no demographic or insurance characteristics associated with receipt of MAC prophylaxis.
Conclusions: The overall prevalence of OI prophylaxis has increased since the mid-1990s, and previous racial and HIV risk factor disparities in receipt of OI prophylaxis have waned. Integration into the healthcare system is an important correlate of receiving OI prophylaxis.
Similar articles
-
Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.MMWR CDC Surveill Summ. 1999 Apr 16;48(2):1-22. MMWR CDC Surveill Summ. 1999. PMID: 12412613
-
Underuse of primary Mycobacterium avium complex and Pneumocystis carinii prophylaxis in the United States.J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):340-4. doi: 10.1097/00126334-200112010-00006. J Acquir Immune Defic Syndr. 2001. PMID: 11707670
-
Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001.J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):96-103. doi: 10.1097/00126334-200501010-00017. J Acquir Immune Defic Syndr. 2005. PMID: 15608532
-
Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?Drugs. 2004;64(7):679-92. doi: 10.2165/00003495-200464070-00001. Drugs. 2004. PMID: 15025543 Review.
-
Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.Clin Infect Dis. 2000 Apr;30 Suppl 1:S5-14. doi: 10.1086/313843. Clin Infect Dis. 2000. PMID: 10770911 Review.
Cited by
-
Structures of care in the clinics of the HIV Research Network.AIDS Patient Care STDS. 2008 Dec;22(12):1007-13. doi: 10.1089/apc.2008.0093. AIDS Patient Care STDS. 2008. PMID: 19072107 Free PMC article.
-
Increase in CD4 count among new enrollees in HIV care in the modern antiretroviral therapy era.J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):84-90. doi: 10.1097/QAI.0000000000000228. J Acquir Immune Defic Syndr. 2014. PMID: 24872131 Free PMC article.
-
Inpatient health services utilization among HIV-infected adult patients in care 2002-2007.J Acquir Immune Defic Syndr. 2010 Mar;53(3):397-404. doi: 10.1097/QAI.0b013e3181bcdc16. J Acquir Immune Defic Syndr. 2010. PMID: 19841589 Free PMC article.
-
Substance abuse treatment in human immunodeficiency virus: the role of patient-provider discussions.J Subst Abuse Treat. 2008 Oct;35(3):294-303. doi: 10.1016/j.jsat.2007.11.005. Epub 2008 Mar 7. J Subst Abuse Treat. 2008. PMID: 18329222 Free PMC article.
-
The impact of illicit drug use and substance abuse treatment on adherence to HAART.AIDS Care. 2007 Oct;19(9):1134-40. doi: 10.1080/09540120701351888. AIDS Care. 2007. PMID: 18058397 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials